JP2023551249A5 - - Google Patents
Info
- Publication number
- JP2023551249A5 JP2023551249A5 JP2023531700A JP2023531700A JP2023551249A5 JP 2023551249 A5 JP2023551249 A5 JP 2023551249A5 JP 2023531700 A JP2023531700 A JP 2023531700A JP 2023531700 A JP2023531700 A JP 2023531700A JP 2023551249 A5 JP2023551249 A5 JP 2023551249A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- alkylenyl
- pharmaceutical composition
- controlled
- release pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2020000087A CU24720B1 (es) | 2020-11-24 | 2020-11-24 | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
| CU2020-0087 | 2020-11-24 | ||
| PCT/CU2021/050012 WO2022111742A1 (es) | 2020-11-24 | 2021-11-18 | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023551249A JP2023551249A (ja) | 2023-12-07 |
| JP2023551249A5 true JP2023551249A5 (cg-RX-API-DMAC7.html) | 2024-11-25 |
Family
ID=80034851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023531700A Pending JP2023551249A (ja) | 2020-11-24 | 2021-11-18 | アルツハイマー病の治療のためのマルチターゲット治療薬としてのナフタレン誘導体の医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240299334A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4252749A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023551249A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230118112A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116829137A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021388673A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3200071A1 (cg-RX-API-DMAC7.html) |
| CU (1) | CU24720B1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023006072A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022111742A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119523898A (zh) * | 2024-12-02 | 2025-02-28 | 肇庆学院 | 多靶点药物的经鼻给药制剂及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4225730C2 (de) | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
| US20040254146A1 (en) | 2002-05-21 | 2004-12-16 | Nastech Pharmaceutical Company Inc. | Carboxylate salts of galantamine and their pharmaceutical use |
| US20030225031A1 (en) | 2002-05-21 | 2003-12-04 | Quay Steven C. | Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid |
| CN1621039A (zh) | 2003-11-25 | 2005-06-01 | 上海医药工业研究院 | 石杉碱甲及其衍生物或其盐的经鼻脑靶向制剂 |
| EP1715843A1 (en) | 2004-01-29 | 2006-11-02 | Neuromolecular Inc. | Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions |
| WO2006009769A1 (en) | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Modified release formulation of memantine |
| US8058291B2 (en) | 2005-04-06 | 2011-11-15 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of CNS-related conditions |
| EP2623099A1 (en) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
| WO2007002497A1 (en) | 2005-06-23 | 2007-01-04 | Envivo Pharmaceuticals, Inc. | Method of treating neurological disorders using clotrimazole and derivatives thereof |
| US20070141148A1 (en) * | 2005-11-30 | 2007-06-21 | Merz Pharma Gmbh & Co. Kgaa | Neramexane MR matrix tablet |
| US7745670B2 (en) * | 2008-06-27 | 2010-06-29 | Codman & Shurtleff, Inc. | Curcumin-Resveratrol hybrid molecule |
| CU23844B1 (es) | 2009-04-17 | 2012-10-15 | Ct De Neurociencias De Cuba | Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer |
| CU20130027A7 (es) * | 2013-02-28 | 2014-10-30 | Ct De Neurociencias De Cuba | Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales |
| CU24583B1 (es) * | 2018-11-06 | 2022-02-04 | Centro De Neurociencias De Cuba | Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri) |
-
2020
- 2020-11-24 CU CU2020000087A patent/CU24720B1/es unknown
-
2021
- 2021-11-18 MX MX2023006072A patent/MX2023006072A/es unknown
- 2021-11-18 CN CN202180091389.3A patent/CN116829137A/zh active Pending
- 2021-11-18 AU AU2021388673A patent/AU2021388673A1/en not_active Abandoned
- 2021-11-18 US US18/038,494 patent/US20240299334A1/en active Pending
- 2021-11-18 CA CA3200071A patent/CA3200071A1/en active Pending
- 2021-11-18 KR KR1020237020732A patent/KR20230118112A/ko active Pending
- 2021-11-18 WO PCT/CU2021/050012 patent/WO2022111742A1/es not_active Ceased
- 2021-11-18 EP EP21848149.7A patent/EP4252749A1/en active Pending
- 2021-11-18 JP JP2023531700A patent/JP2023551249A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1137684C (zh) | 用碱性试剂稳定的药物组合物 | |
| EP2760821B1 (en) | Choline salt of an anti-inflammatory substituted cyclobutenedione compound | |
| US10786507B2 (en) | Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof | |
| US20090208583A1 (en) | Tablets comprising candesartan cilexetil | |
| KR101257919B1 (ko) | 콜린 알포세레이트 또는 이의 약학적으로 허용되는 염을 포함하는 경구용 고형 제제 및 이의 제조방법 | |
| NO20066041L (no) | Anvendelse av substituerte kinolinderivater for behandlingen og legemiddelresistente mykobakterielle sykdommer | |
| MXPA05005667A (es) | Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescente. | |
| JP2022123032A (ja) | エダラボン医薬組成物 | |
| JP2003535895A5 (cg-RX-API-DMAC7.html) | ||
| BG65472B1 (bg) | Използване на саредутант и неговите фармацевтичноприемливи соли за приготвяне на лекарствено средство за използване за лечение или профилактика на голямо депресивно разтройство | |
| JP2019123703A (ja) | ダサチニブを有効成分とする医薬錠剤及びその製造方法 | |
| JP2017048174A (ja) | 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤 | |
| SK100998A3 (en) | Pharmaceutical compositions of cilansetron stabilized against racemisation | |
| US20080260785A1 (en) | Paroxetine compositions | |
| JP2007197410A (ja) | フィルムコーティング錠 | |
| US20060020040A1 (en) | Bupropion hydrochloride solid dosage forms | |
| JP2002284679A (ja) | 安定な甲状腺ホルモン含有固形製剤組成物 | |
| JP2000336032A (ja) | ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物 | |
| JP3597823B2 (ja) | 固形製剤 | |
| US20200237744A1 (en) | Antimicrobial Compositions with Effervescent Agents | |
| WO2022111742A4 (es) | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer | |
| JP2017095441A (ja) | アジルサルタン含有医薬組成物、医薬組成物におけるアジルサルタンの安定化方法、及びアジルサルタンの安定化剤 | |
| AU2017251803B2 (en) | Choline salt of an anti-inflammatory substituted cyclobutenedione compound | |
| KR20070102563A (ko) | 정신병치료제를 함유하는 조절방출형 조성물 | |
| JP2024539116A5 (cg-RX-API-DMAC7.html) |